

Wolfgang Greiner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2180424/publications.pdf>

Version: 2024-02-01

108
papers

4,595
citations

186209

28
h-index

114418

63
g-index

140
all docs

140
docs citations

140
times ranked

6156
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. <i>Quality of Life Research</i> , 2010, 19, 875-886.	1.5	574
2	Barriers and Strategies in Guideline Implementation—A Scoping Review. <i>Healthcare (Switzerland)</i> , 2016, 4, 36.	1.0	509
3	A single European currency for EQ-5D health states. <i>European Journal of Health Economics</i> , 2003, 4, 222-231.	1.4	388
4	Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study. <i>Quality of Life Research</i> , 2010, 19, 887-897.	1.5	325
5	German Value Set for the EQ-5D-5L. <i>Pharmacoeconomics</i> , 2018, 36, 663-674.	1.7	316
6	Effects of an Internet intervention (Deprexis) on severe depression symptoms: Randomized controlled trial. <i>Internet Interventions</i> , 2015, 2, 48-59.	1.4	149
7	Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. <i>European Journal of Health Economics</i> , 2020, 21, 1245-1257.	1.4	148
8	German Recommendations on Health Economic Evaluation: Third and Updated Version of the Hanover Consensus. <i>Value in Health</i> , 2008, 11, 539-544.	0.1	138
9	Effects of a Psychological Internet Intervention in the Treatment of Mild to Moderate Depressive Symptoms: Results of the EVIDENT Study, a Randomized Controlled Trial. <i>Psychotherapy and Psychosomatics</i> , 2016, 85, 218-228.	4.0	124
10	Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. <i>Pharmacoeconomics</i> , 2016, 34, 227-244.	1.7	97
11	EQ-5D-Y as a Health-Related Quality of Life Instrument for Children and Adolescents: The Instrument's Characteristics, Development, Current Use, and Challenges of Developing Its Value Set. <i>Value in Health</i> , 2019, 22, 31-37.	0.1	85
12	Cost of care and clinical condition in paediatric cystic fibrosis patients. <i>Journal of Cystic Fibrosis</i> , 2003, 2, 84-90.	0.3	72
13	Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective. <i>Value in Health</i> , 2018, 21, 1291-1298.	0.1	70
14	Cataract Surgery and the Development or Progression of Age-related Macular Degeneration: A Systematic Review. <i>Survey of Ophthalmology</i> , 2008, 53, 359-367.	1.7	61
15	Can adult weights be used to value child health states? Testing the influence of perspective in valuing EQ-5D-Y. <i>Quality of Life Research</i> , 2015, 24, 2519-2539.	1.5	54
16	Medical effectiveness and safety of conventional compared to laparoscopic incisional hernia repair: A systematic review. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2007, 21, 2127-2136.	1.3	48
17	The EVIDENT-trial: protocol and rationale of a multicenter randomized controlled trial testing the effectiveness of an online-based psychological intervention. <i>BMC Psychiatry</i> , 2013, 13, 239.	1.1	47
18	EQ-5D-Y-5L: developing a revised EQ-5D-Y with increased response categories. <i>Quality of Life Research</i> , 2019, 28, 1951-1961.	1.5	47

#	ARTICLE	IF	CITATIONS
19	A Multinational Economic Evaluation of rhDNase in the Treatment of Cystic Fibrosis. International Journal of Technology Assessment in Health Care, 1996, 12, 52-61.	0.2	45
20	The EQ-HWB: Overview of the Development of a Measure of Health and Wellbeing and Key Results. Value in Health, 2022, 25, 482-491.	0.1	45
21	Methods for determining cost-benefit ratios for pharmaceuticals in Germany. European Journal of Health Economics, 2007, 8, 5-31.	1.4	44
22	Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. BMC Public Health, 2015, 15, 533.	1.2	40
23	HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. European Journal of Health Economics, 2020, 21, 1421-1437.	1.4	38
24	Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions—Report of the ISPOR Stated Preference Research Special Interest Group. Value in Health, 2020, 23, 831-841.	0.1	37
25	EQ-5D-5L reference values for the German general elderly population. Health and Quality of Life Outcomes, 2021, 19, 76.	1.0	36
26	Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. European Journal of Health Economics, 2015, 16, 471-488.	1.4	32
27	Valuation of Child Health-Related Quality of Life in the United States. Health Economics (United) Tj ETQq1 1 0.784314 rgBT /Overlo 0.8	0.8	32
28	Defining and Predicting Patterns of Early Response in a Web-Based Intervention for Depression. Journal of Medical Internet Research, 2017, 19, e206.	2.1	31
29	Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany. Applied Health Economics and Health Policy, 2013, 11, 509-521.	1.0	30
30	Healthcare costs and resource utilization of asthma in Germany: a claims data analysis. European Journal of Health Economics, 2016, 17, 195-201.	1.4	30
31	The patient-level effect of the cost of Cancer care — financial burden in German Cancer patients. BMC Cancer, 2020, 20, 529.	1.1	30
32	Epidemiology and economic burden of measles, mumps, pertussis, and varicella in Germany: a systematic review. International Journal of Public Health, 2016, 61, 847-860.	1.0	29
33	Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. European Journal of Health Economics, 2006, 7, 290-296.	1.4	28
34	Bridging the “digital divide”: A comparison of use and effectiveness of an online intervention for depression between Baby Boomers and Millennials. Journal of Affective Disorders, 2018, 236, 243-251.	2.0	25
35	Epidemiology and cost of seasonal influenza in Germany - a claims data analysis. BMC Public Health, 2019, 19, 1090.	1.2	25
36	Developing a New Generic Health and Wellbeing Measure: Psychometric Survey Results for the EQ-HWB. Value in Health, 2022, 25, 525-533.	0.1	25

#	ARTICLE	IF	CITATIONS
37	Time to remission from mild to moderate depressive symptoms: One year results from the EVIDENT-study, an RCT of an internet intervention for depression. Behaviour Research and Therapy, 2017, 97, 154-162.	1.6	24
38	Cost-effectiveness of human papillomavirus vaccination in Germany. Cost Effectiveness and Resource Allocation, 2017, 15, 18.	0.6	24
39	Treatment costs of attention deficit hyperactivity disorder in Germany. European Journal of Health Economics, 2013, 14, 939-945.	1.4	22
40	The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany. Vaccine, 2019, 37, 1692-1701.	1.7	22
41	Current and future effects of varicella and herpes zoster vaccination in Germany – Insights from a mathematical model in a country with universal varicella vaccination. Human Vaccines and Immunotherapeutics, 2016, 12, 1-11.	1.4	21
42	Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?. BioMed Research International, 2015, 2015, 1-9.	0.9	19
43	Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α -2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. European Journal of Health Economics, 2005, 6, 112-123.	1.4	18
44	Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany. European Journal of Health Economics, 2005, 6, 317-321.	1.4	18
45	Influence of demographic changes on the impact of vaccination against varicella and herpes zoster in Germany – a mathematical modelling study. BMC Medicine, 2018, 16, 3.	2.3	18
46	Retrospective analysis into differences in heart failure patients with and without iron deficiency or anaemia. ESC Heart Failure, 2019, 6, 840-855.	1.4	18
47	Considering the societal perspective in economic evaluations: a systematic review in the case of depression. Health Economics Review, 2020, 10, 32.	0.8	18
48	Burden of Herpes Zoster in Adult Patients with Underlying Conditions: Analysis of German Claims Data, 2007–2018. Dermatology and Therapy, 2021, 11, 1009-1026.	1.4	18
49	Feasibility of the EQ-5D in the elderly population: a systematic review of the literature. Quality of Life Research, 2022, 31, 1621-1637.	1.5	18
50	Patient-Reported Financial Distress in Cancer: A Systematic Review of Risk Factors in Universal Healthcare Systems. Cancers, 2021, 13, 5015.	1.7	18
51	Efficacy and cost-effectiveness of the ^{13}C -urea breath test as the primary diagnostic investigation for the detection of Helicobacter pylori infection compared to invasive and non-invasive diagnostic tests. GMS Health Technology Assessment, 2009, 5, Doc14.	2.2	17
52	EQ-5D-Y Value Set for Germany. Pharmacoeconomics, 2022, 40, 217-229.	1.7	17
53	Valuation of the EQ-5D-5L with composite time trade-off for the German population – an exploratory study. Health and Quality of Life Outcomes, 2017, 15, 39.	1.0	16
54	Health economic evaluation of an internet intervention for depression (deprexis), a randomized controlled trial. Health Economics Review, 2020, 10, 19.	0.8	16

#	ARTICLE	IF	CITATIONS
55	An Innovative Telemedical Network to Improve Infectious Disease Management in Critically Ill Patients and Outpatients (TELnet@NRW): Stepped-Wedge Cluster Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2022, 24, e34098.	2.1	16
56	Cost-Utility Analysis of Eprosartan Compared to Enalapril in Primary Prevention and Nitrendipine in Secondary Prevention in Europeâ€™The HEALTH Model. <i>Value in Health</i> , 2009, 12, 857-871.	0.1	15
57	Application study of the EQ-5D-5L in oncology: linking self-reported quality of life of patients with advanced or metastatic colorectal cancer to clinical data from a German tumor registry. <i>Health Economics Review</i> , 2020, 10, 40.	0.8	14
58	Health economic evaluation of disease management programs. <i>European Journal of Health Economics</i> , 2005, 6, 191-196.	1.4	13
59	Regional differences of outpatient physician supply as a theoretical economic and empirical generalized linear model. <i>Human Resources for Health</i> , 2015, 13, 85.	1.1	13
60	Health economic evaluation of a web-based intervention for depression: the EVIDENT-trial, a randomized controlled study. <i>Health Economics Review</i> , 2019, 9, 16.	0.8	13
61	Generation, Selection, and Face Validation of Items for a New Generic Measure of Quality of Life: The EQ-HWB. <i>Value in Health</i> , 2022, 25, 512-524.	0.1	12
62	High-Expenditure Disease in the EU-28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes?. <i>PharmacoEconomics - Open</i> , 2021, 5, 385-396.	0.9	11
63	To What Extent Do Patient Preferences Differ From General Population Preferences?. <i>Value in Health</i> , 2021, 24, 1343-1349.	0.1	11
64	Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany. <i>Value in Health</i> , 2021, 24, 32-40.	0.1	10
65	Optimization of sepsis therapy based on patient-specific digital precision diagnostics using next generation sequencing (DigiSep-Trial)â€™study protocol for a randomized, controlled, interventional, open-label, multicenter trial. <i>Trials</i> , 2021, 22, 714.	0.7	10
66	The INFLuence of Remote monitoring on Anxiety/depReSSion, quality of lifE, and Device acceptance in ICD patients: a prospective, randomized, controlled, single-center trial. <i>Clinical Research in Cardiology</i> , 2021, 110, 789-800.	1.5	9
67	Comparison of Adult and Adolescent Preferences Toward EQ-5D-Y-3L Health States. <i>Value in Health</i> , 2021, 24, 1350-1359.	0.1	9
68	4 Der EQ-5D der EuroQol-Gruppe. , 2012, , 411-422.		9
69	Effectiveness of the application of an electronic medication management support system in patients with polypharmacy in general practice: a study protocol of cluster-randomised controlled trial (AdAM). <i>BMJ Open</i> , 2021, 11, e048191.	0.8	8
70	Market access and value-based pricing of digital health applications in Germany. <i>Cost Effectiveness and Resource Allocation</i> , 2022, 20, .	0.6	8
71	Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany. <i>Breast Care</i> , 2009, 4, 389-396.	0.8	6
72	A DELPHI study on aspects of study design to overcome knowledge gaps on the burden of disease caused by serogroup B invasive meningococcal disease. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 87.	1.0	6

#	ARTICLE	IF	CITATIONS
73	An exclusive human milk diet for very low birth weight newbornsâ€”A cost-effectiveness and EVPI study for Germany. PLoS ONE, 2019, 14, e0226496.	1.1	6
74	Reduction of potentially inappropriate medication in the elderly: design of a cluster-randomised controlled trial in German primary care practices (RIME). Therapeutic Advances in Drug Safety, 2020, 11, 204209862091845.	1.0	6
75	Wirtschaftliche Potentiale individualisierter Medizin. PharmacoEconomics - German Research Articles, 2011, 9, 45-54.	0.1	5
76	Population size and self-reported characteristics and sexual preferences of men-who-have-sex-with-men (MSM) in Germany based on social network data. PLoS ONE, 2019, 14, e0212175.	1.1	4
77	Health economic burden of patients with phenylketonuria (PKU) â€” A retrospective study of German health insurance claims data. Molecular Genetics and Metabolism Reports, 2021, 27, 100764.	0.4	4
78	Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease. GMS Health Technology Assessment, 2009, 5, Doc16.	2.2	4
79	Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroupâ€”B Invasive Meningococcal Disease. Infectious Diseases and Therapy, 2022, 11, 367-387.	1.8	4
80	Epidemiology and economic burden of meningococcal disease in Germany: A systematic review. Vaccine, 2022, 40, 1932-1947.	1.7	4
81	Scientific Guidelines and Their Implementation in Health Policy. Value in Health, 2008, 11, 547-548.	0.1	3
82	HTA in Germany: very special and specific. European Journal of Health Economics, 2010, 11, 1-3.	1.4	3
83	BevÃ¶lkerungsentwicklung und soziale Pflegeversicherung in Deutschland. Der Einfluss von demografischen Faktoren auf das VerhÃ4ltnis von potenziellen Beitragszahlern und Leistungsbeziehern. Zeitschrift Fur Sozialreform, 2013, 59, 433-458.	0.7	3
84	Kollektiv-ergÃ4nzende Kapitaldeckung in der sozialen Pflegeversicherung â€” Wirkungen des Pflegevorsorgefonds auf die Beitragssatzentwicklung. Zeitschrift Fur Sozialreform, 2015, 61, 199-224.	0.7	3
85	Welchen Beitrag kann die GesundheitsÃ¶konomie im Kontext von Public Health leisten?. Public Health Forum, 2018, 26, 283-285.	0.1	3
86	Effectiveness of a multi-component community-based care approach for older people at risk of care dependency - results of a prospective quasi-experimental study. BMC Geriatrics, 2022, 22, 348.	1.1	3
87	Cost-effectiveness of smoking prevention measures in adolescents. Zeitschrift Fur Gesundheitswissenschaften, 2008, 16, 3-11.	0.8	2
88	Der Kinder- und Jugendreport der DAK-Gesundheit: Eine neue Datengrundlage fÃ¼r die pÃ4diatrische Gesundheitsforschung. Public Health Forum, 2019, 27, 324-326.	0.1	2
89	Developing and testing a cognitive bolt-on for the EQ-5D-Y (Youth). Quality of Life Research, 2022, 31, 215-229.	1.5	2
90	Childhood Allergy and tolerance: Biomarkers and Predictors (CHAMP) and quality of life. Pediatric Allergy and Immunology, 2022, 33, .	1.1	2

#	ARTICLE	IF	CITATIONS
91	Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors. <i>GMS Health Technology Assessment</i> , 2009, 5, Doc04.	2.2	2
92	Telemedizin â€œ Bewertung des Nutzens. , 2021, , 483-496.		2
93	Behavioural and skill-based early interventions in children with autism spectrum disorders. <i>GMS Health Technology Assessment</i> , 2009, 5, Doc10.	2.2	2
94	Use of an electronic medication management support system in patients with polypharmacy in general practice: study protocol of a quantitative process evaluation of the AdAM trial. <i>Therapeutic Advances in Drug Safety</i> , 2022, 13, 204209862110732.	1.0	2
95	Feasibility properties of the EQ-5D-3L and 5L in the general population: evidence from the GP Patient Survey on the impact of age. <i>Health Economics Review</i> , 2022, 12, 28.	0.8	2
96	Kosten sozialrechtlich anerkannter PflegebedÃ¼rftigkeit im Querschnitt. <i>Zeitschrift Fur Sozialreform</i> , 2014, 60, 349-378.	0.7	1
97	FrÃ¼he Arzneimittelnutzenbewertung â€œ RÃ¼ckblick und Ausblick. <i>Public Health Forum</i> , 2017, 25, 235-237.	0.1	1
98	Entwicklung der LeistungsempfÃ¤ngerzahlen in der Gesetzlichen Pflegeversicherung â€œ Zum Einfluss unterschiedlicher MorbiditÃ¤tsannahmen auf die Entwicklung der sozialrechtlich anerkannten PflegebedÃ¼rftigkeit in Deutschland. <i>Schmollers Jahrbuch</i> , 2014, 134, 209-236.	0.2	1
99	Burden of CIN2+â€™diagnoses and conizations in women aged 18â€™45 yearsâ€™a retrospective secondary data analysis of German statutory health insurance claims data. <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 2077-2092.	0.8	1
100	Healthcare Costs and Resource Use Associated With Cervical Intraepithelial Neoplasia and Cervical Conization: A Retrospective Study of German Statutory Health Insurance Claims Data. <i>Journal of Health Economics and Outcomes Research</i> , 2022, 9, 128-139.	0.6	1
101	Methods of Economic Evaluation for the German Statutory Healthcare System. <i>Pharmacoeconomics</i> , 2009, 27, 265.	1.7	0
102	PP177 Health Preference Research In Europe: A Review Of Its Use. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 70-70.	0.2	0
103	Empfehlungen zu gesundheitsÃ¶konomischen Methoden und Designs in Public Health. <i>Public Health Forum</i> , 2000, 8, 7-10.	0.1	0
104	Title is missing!. , 2019, 14, e0226496.		0
105	Title is missing!. , 2019, 14, e0226496.		0
106	Title is missing!. , 2019, 14, e0226496.		0
107	Title is missing!. , 2019, 14, e0226496.		0
108	Letter to the editor by Rosslenbroich, Greiner, Gensorowsky, Grosser, Hasebrook, Schaumburg, Raschke with regard to: Establishment of an interdisciplinary board for bone and joint by Otto-Lambertz et al. https://doi.org/10.1007/s15010-021-01676-9 . <i>Infection</i> , 2022, , 1.	2.3	0